Page 62 - 86_01
P. 62
ANALES
RANF
www.analesranf.com
dritic cells exposed to MVA-based HIV-1 vaccine induce highly functional 72. Hurst J, Hoffmann M, Pace M, Williams JP, Thornhill J, Hamlyn E, et al.
HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals. PloS Immunological biomarkers predict HIV-1 viral rebound after treatment in-
one. 2011;6(5):e19644. terruption. Nat Commun. 2015;6:8495.
61. García F, Bernaldo de Quiros JC, Gómez CE, Perdiguero B, Nájera JL, Ji-
ménez V, et al. Safety and immunogenicity of a modified pox vector-based 73. Rosas-Umbert M, Mothe B, Noguera-Julian M, Bellido R, Puertas MC,
HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of Carrillo J, et al. Virological and immunological outcome of treatment in-
HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase terruption in HIV-1-infected subjects vaccinated with MVA-B. PloS one.
I clinical trial (RISVAC02). Vaccine. 2011;29(46):8309-16. 2017;12(9):e0184929.
62. Gómez CE, Nájera JL, Perdiguero B, García-Arriaza J, Sorzano CO, Jiménez
V, et al. The HIV/AIDS vaccine candidate MVA-B administered as a single 74. Neidich SD, Fong Y, Li SS, Geraghty DE, Williamson BD, Young WC, et
immunogen in humans triggers robust, polyfunctional, and selective effector al. Antibody Fc effector functions and IgG3 associate with decreased HIV-
memory T cell responses to HIV-1 antigens. J. Virol. 2011;85(21):11468- 1 risk. J Clin Invest. 2019.
78.
63. Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: 75. Perdiguero B, Raman SC, Sánchez-Corzo C, Sorzano COS, Valverde JR,
what we know, what we don't know, what we should know. Nat Med. Esteban M, et al. Potent HIV-1-Specific CD8 T Cell Responses Induced in
2004;10(8):806-10. Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the
64. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson HIV Vaccine MVA-B. Viruses. 2018;10(8).
L, et al. Profound early control of highly pathogenic SIV by an effector me-
mory T-cell vaccine. Nature. 2011;473(7348):523-7. 76. Perdiguero B, Sánchez-Corzo C, CO SS, Mediavilla P, Saiz L, Esteban M,
65. Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, et al. Phase et al. Induction of Broad and Polyfunctional HIV-1-Specific T Cell Res-
1 safety and immunogenicity testing of DNA and recombinant modified ponses by the Multiepitopic Protein TMEP-B Vectored by MVA Virus. Vac-
vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis. cines. 2019;7(3).
2011;203(5):610-9.
66. Goepfert PA, Elizaga ML, Seaton K, Tomaras GD, Montefiori DC, Sato A, 77. Perdiguero B, Sánchez-Corzo C, Sorzano COS, Saiz L, Mediavilla P, Este-
et al. Specificity and 6-month durability of immune responses induced by ban M, et al. A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-
DNA and recombinant modified vaccinia Ankara vaccines expressing HIV- GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and
1 virus-like particles. J Infect Dis. 2014;210(1):99-110. Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunc-
67 Guardo AC, Gómez CE, Díaz-Brito V, Pich J, Arnaiz JA, Perdiguero B, et al. tional HIV-1-Specific T Cell and Antibody Responses. Viruses.
Correction: Safety and vaccine-induced HIV-1 immune responses in healthy 2019;11(2).
volunteers following a late MVA-B boost 4 years after the last immunization.
PloS one. 2018;13(4):e0195915. 78. Goebel SJ, Johnson GP, Perkus ME, Davis SW, Winslow JP, Paoletti E.
68. García-Arriaza J, Arnaez P, Jiménez JL, Gómez CE, Muñoz-Fernández MA, The complete DNA sequence of vaccinia virus. Virology.
Esteban M. Vector replication and expression of HIV-1 antigens by the 1990;179(1):247-66, 517-63.
HIV/AIDS vaccine candidate MVA-B is not affected by HIV-1 protease in-
hibitors. Virus Res. 2012;167(2):391-6. 6. DECLARACIÓN DE TRANSPARENCIA
69. Mothe B, Climent N, Plana M, Rosas M, Jiménez JL, Muñoz-Fernández El autor/a de este artículo declara no tener ningún tipo de con-
MA, et al. Safety and immunogenicity of a modified vaccinia Ankara-based flicto de intereses respecto a lo expuesto en la presente revisión.
HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination
with a drug to reactivate latent HIV-1. J. Antimicrob. Ther. Si desea citar nuestro artículo:
2015;70(6):1833-42. MVA-B como candidato vacunal frente al VIH/SIDA: de la investi-
70. Gómez CE, Perdiguero B, García-Arriaza J, Cepeda V, Sánchez-Sorzano
CO, Mothe B, et al. A Phase I Randomized Therapeutic MVA-B Vaccination gación básica a los ensayos clínicos profiláctico y terapéutico.
Improves the Magnitude and Quality of the T Cell Immune Responses in Carmen Elena Gómez Rodríguez
HIV-1-Infected Subjects on HAART. PloS one. 2015;10(11):e0141456. An Real Acad Farm (Internet).
71. Rallon N, Mothe B, López Bernaldo de Quiros JC, Plana M, Ligos JM, Mon-
toya M, et al. Balance between activation and regulation of HIV-specific An Real Acad Farm Vol. 86. Nº 1 (2020) · pp. 29 -60
CD8+ T-cell response after modified vaccinia Ankara B therapeutic vacci-
nation. AIDS. 2016;30(4):553-62.
MVA-B como candidato vacunal frente al VIH/SIDA: de la inves-
60 tigación básica a los ensayos clínicos profiláctico y terapéutico.
Carmen Elena Gómez Rodríguez
An Real Acad Farm Vol. 86. Nº 1 (2020) · pp. 29 -60
